CLINUVEL Secures EMA Scientific Advice for Pivotal Vitiligo Phase III Study
CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.
- EMA endorses 'totality of evidence' for SCENESSE vitiligo trial
- Phase III CUV107 study to enrol 300 patients starting second half 2026
- Primary endpoint focuses on 50% repigmentation excluding hands and feet
- Patient-reported outcomes and photographic review integral to evaluation
- Systemic treatment prioritised for darker skin phototypes IV-VI
EMA Finalises Design for SCENESSE Vitiligo Study
CLINUVEL Pharmaceuticals (ASX:CUV) has cleared a significant regulatory hurdle with the European Medicines Agency (EMA) handing down final scientific advice on its planned Phase III CUV107 trial. This pivotal study will evaluate SCENESSE® (afamelanotide) as a systemic treatment for adults and adolescents with non-segmental vitiligo, a skin disorder characterised by patchy depigmentation.
The EMA’s endorsement comes after over a year of dialogue, including multiple formal submissions and a critical discussion with the Scientific Advice Working Party. The regulator has embraced a "totality of evidence" approach, meaning the trial’s primary endpoint; achieving 50% or more repigmentation across the body (excluding hands and feet); will be assessed alongside patient-reported outcomes and clinical data from previous studies. This comprehensive evaluation reflects the complexity of measuring efficacy in vitiligo, where visible changes and patient perception are paramount.
Study Focuses on Visual and Patient-Centred Outcomes
Photographic documentation will play a central role in the CUV107 trial, with centralised reviews assessing changes from baseline pigmentation. Secondary endpoints include achieving 75% repigmentation of the head and neck (excluding lips and hands). Five separate patient and physician surveys are integrated to capture subjective experiences, underscoring the EMA’s recognition of patients’ perspectives in evaluating treatment impact.
The EMA also highlighted that patients with darker skin tones (Fitzpatrick IV-V-VI) stand to benefit most from systemic therapy, as the contrast between affected and unaffected skin makes vitiligo more visible and socially impactful in these populations. This focus could shape recruitment and eventual market positioning.
Trial Set to Begin in Second Half 2026 Amid Strategic Momentum
The 300-patient CUV107 trial is slated to commence in the second half of 2026, marking a critical step towards potential marketing authorisation. Dr Emilie Rodenburger, CLINUVEL’s Director of Global Clinical Affairs, noted the EMA’s thorough engagement as a positive sign, stating the agency is now fully informed on the program and expected outcomes.
This regulatory milestone follows CLINUVEL’s recent strategic moves, including the retention of CEO Philippe Wolgen to steer the company through this pivotal growth phase and the prioritisation of the vitiligo clinical program amid plans for a Nasdaq listing. The company’s focus on systemic photoprotection and repigmentation therapies reflects a broader ambition to address unmet needs in dermatology and rare diseases vitiligo program takes centre stage.
SCENESSE is already approved in several regions for erythropoietic protoporphyria, but this vitiligo indication would represent a significant expansion into a large, underserved market with no currently approved systemic treatments for extensive depigmentation.
Bottom Line?
The EMA’s final advice sets a clear regulatory path for CLINUVEL’s vitiligo trial, but ultimate approval hinges on the trial’s ability to demonstrate meaningful repigmentation and patient benefit.
Questions in the middle?
- How will CLINUVEL manage recruitment to prioritise patients with darker skin tones as advised by EMA?
- What competitive dynamics will emerge if SCENESSE gains approval as the first systemic vitiligo treatment?
- How might patient-reported outcomes influence regulatory and commercial acceptance of SCENESSE?
